Tuesday, April 08, 2014 6:54:07 AM
Under the terms of the rights offering, the company is distributing, at no charge to the holders of its common stock as of 5:00 p.m., New York City time, on March 14, 2014, which was established as the record date for the rights offering, 0.063921 non-transferable subscription rights for each share of common stock owned on the record date, as more fully described in the prospectus relating to the rights offering. Each whole subscription right will allow the holder to subscribe to purchase one share of common stock at a subscription price of $16.80 per share. In the aggregate, the company intends to issue 2,678,571 shares of common stock in connection with the rights offering.
The subscription rights may be exercised until 5:00 p.m. New York City time, on April 28, 2014, as more fully described in the prospectus. The rights offering period may not be extended. Any fractional rights remaining after aggregating all of the subscription rights issued to a stockholder will be rounded down to the nearest whole number, and no stockholder will receive any shares with respect to fractional rights that are rounded down.
The company has received a standby commitment from the Jack W. Schuler Living Trust and the Schuler Family Foundation. The standby purchaser has agreed to purchase any and all shares of common stock that are not subscribed for by stockholders in connection with the rights offering. Upon completion of the rights offering, the company will receive gross proceeds of approximately $45,000,000 before expenses. The purpose of the rights offering is to raise equity capital in a cost-effective manner that gives all of the company's existing stockholders the opportunity to participate on a pro rata basis. The net proceeds of the offering will be used for working capital and specifically to fund the company's business plan and product commercialization efforts.
A Registration Statement relating to these securities has been filed with the SEC and was declared effective on April 7, 2014. A copy of the prospectus forming a part of the Registration Statement may be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting Steve Reichling at (520) 365-3100. For questions about the rights offering, including questions about subscription procedures and requests for additional copies of the prospectus, contact Broadridge Corporate Issuer Solutions, Inc. at (855) 793-5068. Broadridge is acting as the Subscription and Information Agent for the rights offering on behalf of the company.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
- See more at: http://www.noodls.com/view/A68E76F6CBC5AB286AF6AA42E60360ACE2B3F55D?8327xxx1396899372#sthash.leyT5F9S.dpuf
Recent AXDX News
- Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. • PR Newswire (US) • 05/02/2024 01:30:00 PM
- Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. • PR Newswire (US) • 03/07/2024 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:32:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:31:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:45:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/05/2024 08:59:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:59:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:48:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:12:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 02:20:45 AM
- Form 424B1 - Prospectus [Rule 424(b)(1)] • Edgar (US Regulatory) • 01/23/2024 02:59:53 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:17 AM
- Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement • PR Newswire (US) • 01/19/2024 02:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 12:19:47 PM
- Accelerate Diagnostics Announces Launch of Proposed Public Offering • PR Newswire (US) • 01/16/2024 12:45:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/16/2024 12:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:03:07 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM